spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  selective estrogen receptor modulator 

 HSMN NewsFeed - 27 Sep 2016
Helix Twelve Pharmaceuticals Appoints Fred R. Seddiqui as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2014
Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Jun 2010
New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2009
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2009
QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 27 Apr 2009
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2009
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 22 Apr 2009
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 24 Mar 2009
FABLYN Approved in Europe for the Treatment of Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Mar 2009
Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2009
Pfizer Receives FDA Complete Response Letter for Lasofoxifene
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2008
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2008
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2008
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2008
QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 6 May 2008
GTx Appoints Kenneth S. Robinson, MD to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2008
GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 24 Dec 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
Ligand Earns Milestone Payment as Wyeth Submits European Market Authorization for Bazedoxifene
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Sep 2007
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2007
FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2007
FDA Advisory Committee Recommends Approval of EVISTA for the Reduction of Risk for Invasive Breast Cancer in Two Populations of Postmenopausal Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jul 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2007
GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2007
GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data Highlighted at Press Briefing at Prostate Cancer Symposium of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
GTx Announces That Ostarine Achieved Primary Endpoint of Lean Body Mass and a Secondary Endpoint of Improved Functional Performance in a Phase II Clinical Trial and Reacquisition of Full Rights to GTx SARM Program
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
Eli Lilly and Company Submits New Drug Application for EVISTA for Reduction of Invasive Breast Cancer Risk in Postmenopausal Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2006
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Sep 2006
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Jun 2006
Wyeth Submits Two New Drug Applications for Women's Health Therapies
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
In a Phase III Lipid Interim Analysis, ACAPODENE Treatment Lowered Cholesterol and Raised HDL In Prostate Cancer Patients On Androgen Deprivation Therapy
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
selective estrogen receptor modulator
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.